Skip to main content
HR 6625 117th Congress House

Equal Access to Therapeutics Act

Official title: To prohibit the Secretary of Health and Human Services from issuing guidance intended to restrict access to COVID-19 monoclonal antibody therapies and other treatments.

Introduced: February 7, 2022 See on congress.gov
Health Cardiovascular and respiratory healthCivil actions and liabilityDepartment of Health and Human ServicesDrug therapy
More subjectsShow fewer subjects
Emergency medical services and trauma careFederal officialsGovernment liabilityHealth care coverage and accessHealth facilities and institutionsHealth programs administration and fundingImmunology and vaccinationInfectious and parasitic diseasesMinority healthRacial and ethnic relations
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 8, 2022
Referred to the Subcommittee on Health.
Feb 7, 2022
Referred to the House Committee on Energy and Commerce.
Feb 7, 2022
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 8, 2022

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Equal Access to Therapeutics Act

This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).

Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance.

The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 16
All 16 Republican 11
R
Smith, Jason
Missouri · Mar 17, 2022
 R
Grothman, Glenn
Wisconsin · Feb 9, 2022
Jacobs, Chris
· Feb 9, 2022
Fortenberry, Jeff
· Feb 8, 2022
Gibbs, Bob
· Feb 8, 2022
McKinley, David
· Feb 8, 2022
 R
Van Drew, Jefferson
New Jersey · Feb 8, 2022
 R
Bost, Mike
Illinois · Feb 7, 2022
 R
Cammack, Kat
Florida · Feb 7, 2022
 R
Feenstra, Randy
Iowa · Feb 7, 2022
 R
Garbarino, Andrew R.
New York · Feb 7, 2022
 R
Graves, Sam
Missouri · Feb 7, 2022
Lamborn, Doug
· Feb 7, 2022
 R
Malliotakis, Nicole
New York · Feb 7, 2022
 R
Tenney, Claudia
New York · Feb 7, 2022
 R
Van Duyne, Beth
Texas · Feb 7, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6625: Equal Access to Therapeutics Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6625/
MLA
"H.R. 6625: Equal Access to Therapeutics Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6625/.
Bluebook (legal)
H.R. 6625, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6625/.
Markdown link
[H.R. 6625: Equal Access to Therapeutics Act](https://openamerica.io/bill/117-HR-6625/)
Report a problem